Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(01): 4-5
DOI: 10.1055/s-0041-1733142
Editorial

Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)

Lalit Kumar
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
Roopa Hari Prasad
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
Manju Sengar
Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Cannistra SA. Cancer of ovary. N Eng J Med 2004;351:2519-2529.
  • 2 Brislow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
  • 3 McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med 334;3-6,1996.
  • 4 Piccart M, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin -paclitaxel versus cisplatin cyclophosphamide in women with advanced epithelial ovarian cancer : Three year results. J Nat Cancer Inst 2000;92:699-708.
  • 5 The International Collaborative Ovarian Neoplasms (ICON) Group : Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer. The ICON 3 randomized trial. Lancet 2002;360:505-515.
  • 6 du Bois A, Luck HJ, Meier W Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol. 1997;24(4Suppl 11):S11-28-S11-33.
  • 7 Lal P, Tiwari A, Rastogi N, & Kumar Sh. Epithelial ovarian cancer : an audit of patients treated over 15 years. Ind J Med & Paed Oncol 2006;27:15-22.
  • 8 Junor EJ, Hole DJ, McNulty L, et al. Specialist gynecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients. Br J Obstet Gynecol 1999;106:1130-1136.
  • 9 Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long term survival Gyneco Oncol 1999;72:93-99.
  • 10 Vergote IB, de Wever I, decloedt J, Tjalma W, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Sem Oncol 2000;27(suppl.7):31-36.